Tsirigotis, P., Danylesko, I., Gkirkas, K., Shem-Tov, N., Yerushalmi, R., Stamouli, M., Avigdor, A., Spyridonidis, A., Gauthier, J., Goldstein, G., Apostolidis, J., Mohty, M., Shimoni, A. and Nagler, A. (2016) Brentuximab Vedotin in Combination with or without Donor Lymphocyte Infusion for Patients with Hodgkin Lymphoma after Allogeneic Stem-Cell Transplantation. Bone Marrow Transplant, 51, 1313-1317.
https://doi.org/10.1038/bmt.2016.129

has been cited by the following article:

• TITLE: Brentuximab Vedotin Monotherapy and Combined with Low Dose Donor Lymphocyte Infusion to Control Minimal Residual Disease and Sustain Clinical Remission in a Child with Relapsed Anaplastic Large Cell Lymphoma

  AUTHORS: Alina S. Fedorova, Maria V. Stegantseva, Nina V. Minakovskaya, Olga V. Aleinikova

  KEYWORDS: Anaplastic Large Cell Lymphoma, Relapse, Brentuximab Vedotin, Donor Lymphocyte Infusion, Minimal Residual Disease

  JOURNAL NAME: Journal of Cancer Therapy, Vol.8 No.8, July 28, 2017

  ABSTRACT: Minimal residual disease (MRD) appears to have a strong negative predictive value for disease recurrence in children with anaplastic large cell lymphoma (ALCL). Brentuximab vedotin (BV) can be a therapeutic option for MRD-positive patients to achieve molecular remission and to decrease risk of subsequent relapse. We here report a 4-year-old child with ALCL progression during relapse treatment who received BV as a bridging therapy before haploidentical hematopoietic stem-cell transplantation, and as a maintenance therapy post-transplant alone or combined with simultaneous low dose donor-lymphocyte infusions. MRD monitoring showed a complete molecular response and reflected both BV efficiency and graft-versus-lymphoma effect.